Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Serum hepatitis B virus (HBV) DNA levels and non-invasive liver fibrosis scores are significantly associated with hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients. Nonetheless, the relationship between HBV DNA levels and liver fibrosis scores is unclear. Methods: A historical cohort comprising 6,949 non-cirrhotic Korean CHB patients without significant alanine aminotransferase elevation was investigated. The association of HBV DNA levels with the aspartate aminotransferase to platelet ratio index (APRI) and fibrosis (FIB)-4 score at baseline was analyzed using general linear models. Results: In HBeAg-negative patients (n=4,868), HBV DNA levels correlated linearly with both APRI and FIB-4 scores. In contrast, in HBeAg-positive patients (n=2,081), HBV DNA levels correlated inversely with both APRI and FIB-4 scores. Across the entire cohort, a significant non-linear parabolic relationship was identified between HBV DNA levels and fibrosis scores, independent of age and other covariates. Notably, moderate viral loads (6–7 log10 IU/ mL) corresponded to the highest APRI and FIB-4 scores (P<0.001). Over a median 10-year follow-up, 435 patients (6.3%) developed HCC. Higher APRI scores ≥0.5 and FIB-4 scores ≥1.45 were significantly associated with elevated HCC risk (P<0.001 for both). HBV DNA level remained a significant predictive factor for HCC development, even after adjusting for APRI or FIB-4 scores. Conclusions: HBV viral load is significantly correlated with APRI and FIB-4 scores, and is also associated with HCC risk independent of those scores in CHB patients. These findings suggest that HBV DNA level is associated with hepatocarcinogenesis through both direct and indirect pathways.
Abstract
Background/Aims: Serum hepatitis B virus (HBV) DNA levels and non-invasive liver fibrosis scores are significantly associated with hepatocellular carcinoma (HCC) risk in chronic hepatitis B (CHB) patients. Nonetheless, the relationship between HBV DNA levels and liver fibrosis scores is unclear. Methods: A historical cohort comprising 6,949 non-cirrhotic Korean CHB patients without significant alanine aminotransferase elevation was investigated. The association of HBV DNA levels with the aspartate aminotransferase to platelet ratio index (APRI) and fibrosis (FIB)-4 score at baseline was analyzed using general linear models. Results: In HBeAg-negative patients (n=4,868), HBV DNA levels correlated linearly with both APRI and FIB-4 scores. In contrast, in HBeAg-positive patients (n=2,081), HBV DNA levels correlated inversely with both APRI and FIB-4 scores. Across the entire cohort, a significant non-linear parabolic relationship was identified between HBV DNA levels and fibrosis scores, independent of age and other covariates. Notably, moderate viral loads (6–7 log10 IU/ mL) corresponded to the highest APRI and FIB-4 scores (P<0.001). Over a median 10-year follow-up, 435 patients (6.3%) developed HCC. Higher APRI scores ≥0.5 and FIB-4 scores ≥1.45 were significantly associated with elevated HCC risk (P<0.001 for both). HBV DNA level remained a significant predictive factor for HCC development, even after adjusting for APRI or FIB-4 scores. Conclusions: HBV viral load is significantly correlated with APRI and FIB-4 scores, and is also associated with HCC risk independent of those scores in CHB patients. These findings suggest that HBV DNA level is associated with hepatocarcinogenesis through both direct and indirect pathways.
참고문헌 (36)
- Thomas DL, "Global elimination of chronic hepatitis", N Engl J Med, 380, pp.2041~2050 (2019)
- Foreman KJ, "Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death : reference and alternative scenarios for 2016-40 for 195 countries and territories", Lancet, 392, pp.2052~2090 (2018)
- European Association for the Study of the Liver, "EASL clinical practice guidelines : management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
- Chen CJ, "Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level", JAMA, 295, pp.65~73 (2006)
- Kim GA, "Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients", Aliment Pharmacol Ther, 51, pp.1169~1179 (2020)
- Choi WM, "Non-linear association of baseline viral load with on-treatment hepatocellular carcinoma risk in chronic hepatitis B", Gut, 73, pp.649~658 (2024)
- Choi WM, "Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B", J Clin Invest, 132, pp.e154833~ (2022)
- Suh B, "High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers", Hepatology, 61, pp.1261~1268 (2015)
- Kim MN, "Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gammaglutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients : comparison with liver biopsy", Eur J Gastroenterol Hepatol, 32, pp.433~439 (2020)
- European Association for the Study of the Liver, "EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update", J Hepatol, 75, pp.659~689 (2021)
- Wai CT, "A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C", Hepatology, 38, pp.518~526 (2003)
- Vallet-Pichard A, "FIB-4 : an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest", Hepatology, 46, pp.32~36 (2007)
- Xiao G, "Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis-4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection : a systemic review and metaanalysis", Hepatology, 61, pp.292~302 (2015)
- Hosaka T, "Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection", Hepatology, 58, pp.98~107 (2013)
- Wu CY, "Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B : a nationwide cohort study", Gastroenterology, 147, pp.143~151 (2014)
- Liu J, "Presence of liver inflammation in asian patients with chronic hepatitis B with normal ALT and detectable HBV DNA in absence of liver fibrosis", Hepatol Commun, 6, pp.855~866 (2022)
- Wang J, "Significant histological disease of patients with chronic hepatitis B virus infection in the grey zone", Aliment Pharmacol Ther, 57, pp.464~474 (2023)
- Huang R, "Histological features of chronic hepatitis B patients with normal alanine aminotransferase according to different criteria", Hepatol Commun, 8, pp.e0357~ (2024)
- Choi WM, "Chronic hepatitis B baseline viral load and on-treatment liver cancer risk : a multinational cohort study of HBeAgpositive patients", Hepatology, 80, pp.428~439 (2024)
- Liu S, "Concerns about the inverse relationship between baseline HBV DNA and on-treatment hepatocellular carcinoma risk", J Clin Invest, 132, pp.e161134~ (2022)
- Chen CF, "Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma", Gastroenterology, 141, pp.1240~1248 (2011)
- Chun HS, "PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAgpositive chronic hepatitis B", J Hepatol, 80, pp.20~30 (2024)
- Chemin I, "Hepatitis B virus induced hepatocellular carcinoma", Cancer Lett, 286, pp.52~59 (2009)
- Zoulim F, "Reasons to consider earlier treatment of chronic HBV infections", Gut, 61, pp.333~336 (2012)
- Nkongolo S, "Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8+ T cells", J Clin Invest, 133, pp.e158903~ (2023)
- Luxenburger H, "Liver-resident CD8+T cells in viral hepatitis : not always good guys", J Clin Invest, 133, pp.e165033~ (2023)
- Terrault NA, "AASLD guidelines for treatment of chronic hepatitis B", Hepatology, 63, pp.261~283 (2016)
- Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
- European Association for the Study of the Liver, "EASL 2017clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Kim GA, "High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B", Gut, 67, pp.945~952 (2018)
- Choi GH, "High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation", Aliment Pharmacol Ther, 50, pp.215~226 (2019)
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- Cui F, "Global reporting of progress towards elimination of hepatitis B and hepatitis C", Lancet Gastroenterol Hepatol, 8, pp.332~342 (2023)
- Gleeson J, "Use of liver imaging and biopsy in clinical practice", N Engl J Med, 377, pp.2296~ (2017)
- Kim H, "Molecular epidemiology of hepatitis B virus(HBV)genotypes and serotypes in patients with chronic HBV infection in Korea", Intervirology, 50, pp.52~57 (2007)
- Lin CL, "The clinical implications of hepatitis B virus genotype : recent advances", J Gastroenterol Hepatol, 26(Suppl 1), pp.123~130 (2011)